Admission to trading and first day of dealings in the Company’s ordinary shares took place on 17 February 2021, Cairn Financial Advisers LLP acted as nominated adviser and finnCap Ltd acted as broker. Immediately following Admission, the Company had 12,317,473 ordinary shares in issue and a market capitalisation of approximately £14.5m.
4basebio is a specialist life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. It is the intention of the Company to become a market leader in the manufacture and supply of high purity, synthetic DNA for research, therapeutic and pharmacological use. The immediate objectives of 4bb are to validate and scale its DNA synthesis and advance its collaborations to facilitate the functional validation of its DNA based products and gene delivery solutions.
Heikki Lanckriet, Chief Executive Officer of 4basebio, commented:
“We are delighted to be admitted to AIM. As a Cambridge based company with significant ambitions, we believe AIM is the ideal market to support our further development. We would also like to extend our thanks to our staff, advisors and shareholders who continue to support our ongoing growth strategy.”
Admission follows the transfer of the Company’s corporate seat from Germany to the UK on 22 December 2020 and the conversion of the Company into a ‘United Kingdom Societas’ on 31 December 2020 following the UK’s renegotiation of its relationship with the European Union.
Stephen Hamilton, Partner at Mills & Reeve said:
“Working on this transaction has involved one of the final transfers of a company from the EU to the UK and represents a pivotal point in history. The transfer of corporate seat and AIM listing of the business will mean that further investment and development of the critical work that 4basebio are doing will be grounded in the UK. And of course, Cambridge is at the heart of these developments.”